DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 629 shares of the firm's stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the sale, the executive vice president now directly owns 68,212 shares of the company's stock, valued at $8,611,765. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Michael Jon Brown also recently made the following trade(s):
- On Thursday, March 28th, Michael Jon Brown sold 2,624 shares of DexCom stock. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96.
DexCom Price Performance
Shares of NASDAQ:DXCM opened at $126.65 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a market capitalization of $50.37 billion, a P/E ratio of 81.71, a P/E/G ratio of 2.15 and a beta of 1.23. The firm's 50 day simple moving average is $131.87 and its two-hundred day simple moving average is $119.62.
POTUS in ‘25 Not Biden/Trump, But
From The Freeport Society | Ad
And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.
Click here now to see my urgent election warning.
DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. Research analysts expect that DexCom, Inc. will post 1.77 EPS for the current fiscal year.
Hedge Funds Weigh In On DexCom
Several hedge funds have recently modified their holdings of DXCM. DSM Capital Partners LLC purchased a new position in shares of DexCom in the fourth quarter worth $28,000. Valley National Advisers Inc. lifted its holdings in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock worth $30,000 after buying an additional 103 shares in the last quarter. Riverview Trust Co purchased a new position in shares of DexCom in the first quarter worth $32,000. MV Capital Management Inc. lifted its holdings in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock worth $34,000 after buying an additional 138 shares in the last quarter. Finally, Smithfield Trust Co lifted its holdings in shares of DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company's stock worth $40,000 after buying an additional 165 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on DXCM shares. Raymond James lifted their price target on shares of DexCom from $151.00 to $160.00 and gave the company a "strong-buy" rating in a research report on Friday, April 26th. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 price target for the company. StockNews.com upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research note on Wednesday. Citigroup raised their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a "buy" rating in a research note on Wednesday, April 3rd. Finally, Canaccord Genuity Group raised their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a "buy" rating in a research note on Friday, April 26th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $141.67.
Check Out Our Latest Analysis on DexCom
About DexCom
(
Get Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
